By: Adam Feuerstein | 07/29/14 - 10:26 AM EDT
Fruit pectin is delicious spread on toast, but can an experimental drug derived from fruit pectin be effective as a treatment for fatty liver disease? Not so much, which explains the steep drop in
Galectin's experimental drug GR-MD-02 flopped in a phase I study of nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease. Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo. Galectin deemed the updated results from the phase I study to be a success because patients treated with GR-MD-02 reported no serious side effects, but of course, ineffective placebos rarely raise safety concerns.
Shares of Galectin fell 53% to $6.76 in Tuesday trading.
The stock promoters paid by Galectin to entice retail investors into buying the stock face a tougher challenge going forward.
La Jolla Pharmaceuticals (LJPC) shares were down 12% to $10.35 Tuesday because the company is developing a competing NASH drug which also claims to work in a similar way.
09/16/14 - 01:04 PM EDT
09/15/14 - 10:19 AM EDT
09/12/14 - 09:43 AM EDT
09/11/14 - 01:23 PM EDT
09/10/14 - 03:37 PM EDT
09/16/14 - 12:11 PM EDT
09/15/14 - 10:40 AM EDT
09/14/14 - 15:51 PM EDT
09/13/14 - 12:28 PM EDT
09/12/14 - 11:08 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.